Good quarter imo. I think I’ll miss my cheap buy back in by the looks of things. Still not cheap, but if they keep growing at 30% they will quickly justify the price.
OAR Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025